Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026
Neumora Therapeutics (Nasdaq: NMRA) will report fourth quarter and full year 2025 financial results on Monday, March 30, 2026 and will host a conference call and live webcast at 8:00 a.m. ET.
Rhea-AI Summary
Neumora Therapeutics (Nasdaq: NMRA) will report fourth quarter and full year 2025 financial results on Monday, March 30, 2026 and will host a conference call and live webcast at 8:00 a.m. ET.
According to Neumora Therapeutics, the live webcast will be available on the company website and a replay will be archived for up to 30 days. Participants are advised to register at least 10 minutes before the call.
Positive
- None.
Negative
- None.
Details
News Market Reaction – NMRA
In the Mar 16 session, NMRA declined 4.33%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Earnings call time
- 8:00 a.m. ET
- Scheduled on March 30, 2026 for Q4 and full-year 2025 results
- Cash balance
- $171.5M
- Cash, cash equivalents and marketable securities as of Q3 2025
- Non-dilutive capital
- $40M
- Drawn from existing K2 HealthVentures facility in Q3 2025 update
- CMAI reduction
- 15.7-point reduction
- Mean reduction on CMAI total score in NMRA-511 Phase 1b study
- Placebo-adjusted change
- -7.6 at Week 6
- CMAI placebo-adjusted improvement in elevated-anxiety subgroup
- Placebo-adjusted change
- -5.6 at Week 8
- CMAI placebo-adjusted improvement in elevated-anxiety subgroup
- Discontinuation rate
- 2.5%
- Discontinuations due to TEAEs in NMRA-511 Phase 1b study
- Earnings call date
- March 30, 2026
- Scheduled reporting date for Q4 and full-year 2025 financial results
Historical Context
-
Announcement of participation in Guggenheim Emerging Outlook: Biotech Summit 2026.
-
Outlined 2026 pipeline strategy and multiple anticipated clinical readouts.
-
Reported positive Phase 1b signal-seeking results for NMRA-511 in AD agitation.
-
Reported Q3 2025 results, strong cash position, and extended funding runway.
-
Planned participation in two November 2025 healthcare investor conferences.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that it will host a conference call and live webcast at 8:00 a.m. ET on Monday, March 30, 2026, to report its fourth quarter and full year 2025 financial results and provide a business update.
A live webcast of the event will be available on the events and presentations section of the Company’s website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call.
About Neumora
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the greatest medical challenges of our generation by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients.
Neumora Contact:
Helen Rubinstein
617-402-5700
Helen.Rubinstein@neumoratx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.